Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IMBRUVICA vs ACALABRUTINIB
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in the BTK active site, leading to irreversible inhibition of BTK activity. BTK is a key signaling molecule in the B-cell antigen receptor (BCR) and cytokine receptor pathways, which are involved in the survival, proliferation, and migration of malignant B cells.
Acalabrutinib is a selective, irreversible inhibitor of Bruton tyrosine kinase. It forms a covalent bond with a cysteine residue in the active site, blocking B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival.
Mantle cell lymphoma (MCL) in patients who have received at least one prior therapy,Chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL),Waldenström's macroglobulinemia (WM),Relapsed or refractory marginal zone lymphoma (MZL) in patients who have received at least one prior anti-CD20-based therapy,Chronic graft versus host disease (c GVHD) after failure of one or more lines of systemic therapy,Relapsed or refractory follicular lymphoma (off-label)
Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy,Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
560 mg orally once daily for mantle cell lymphoma; 420 mg orally once daily for chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease.
100 mg orally every 12 hours.
Terminal elimination half-life is approximately 4–6 hours. No clinically relevant accumulation is observed at steady state.
Terminal elimination half-life is approximately 1 hour. Clinical context: short half-life supports twice-daily dosing, but BTK occupancy remains >90% over 12 hours due to irreversible binding.
Ibrutinib is primarily metabolized by cytochrome P450 (CYP) 3A4, and to a minor extent by CYP2D6. The major active metabolite is PCI-45227, which has similar inhibitory activity against BTK. Avoid coadministration with strong or moderate CYP3A4 inhibitors or inducers.
Primarily metabolized by CYP3A4, with minor contributions from CYP2C8 and glutathione conjugation.
Primarily via feces (approximately 80% as metabolites and parent drug); renal excretion accounts for <10% of the dose.
Primarily hepatic metabolism (CYP3A4); fecal excretion accounts for approximately 86% (including 69% as metabolites, 17% as unchanged drug). Renal excretion is minimal (<1% unchanged).
Approximately 97.3% bound to plasma proteins (primarily albumin).
97% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Volume of distribution is approximately 10,000 L (extremely large, indicating extensive tissue distribution, but not typically expressed in L/kg).
Approximately 34 L (approx. 0.5 L/kg for a 70 kg adult), indicating moderate distribution into tissues.
Oral bioavailability is approximately 2.9% (low due to extensive first-pass metabolism and poor absorption; food increases exposure by about 60%).
Oral bioavailability: approximately 70–75% (absolute bioavailability not determined in humans; estimate based on mass balance and exposure data).
No dose adjustment required for GFR ≥ 30 m L/min. For GFR < 30 m L/min, use with caution and monitor closely; no specific dose recommendation available.
No dose adjustment required for Cr Cl ≥30 m L/min. For Cr Cl <30 m L/min, reduce dose to 100 mg orally once daily.
Child-Pugh A: 280 mg orally once daily (starting dose for CLL/SLL, WM, MZL, c GVHD) or 420 mg orally once daily (starting dose for MCL). Child-Pugh B: 140 mg orally once daily (CLL/SLL, WM, MZL, c GVHD) or 280 mg orally once daily (MCL). Child-Pugh C: Not recommended.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 100 mg orally once daily. Child-Pugh C: Avoid use.
Not approved for pediatric use. Safety and efficacy not established.
Not approved for patients <18 years; safety and efficacy not established.
No specific dose adjustment required; patients ≥65 years experienced higher incidence of certain adverse events (e.g., atrial fibrillation, hypertension) in clinical trials; monitor closely.
No specific dose adjustment; monitor for toxicity, especially infections and bleeding.
Hemorrhage: Fatal and serious hemorrhagic events have occurred in patients treated with IMBRUVICA. Major hemorrhage (≥ Grade 3) has occurred in up to 6% of patients. Bleeding events include intracranial hemorrhage, gastrointestinal bleeding, hematuria, and post-procedural hemorrhage. Monitor for signs of bleeding. Consider benefit-risk of surgery and the need for temporary interruption.
No boxed warning is included in the FDA-approved prescribing information.
Hemorrhage: risk of bleeding, including fatal events; consider withholding for at least 3-7 days pre- and post-surgery,Infections: fatal and serious infections have occurred (e.g., pneumonia, sepsis); monitor for infections,Cytopenias: Grade 3/4 neutropenia, thrombocytopenia, and anemia may occur; monitor blood counts,Cardiac arrhythmias: atrial fibrillation and ventricular tachyarrhythmias; monitor electrocardiogram and manage as appropriate,Tumor lysis syndrome: risk in patients with high tumor burden; ensure adequate hydration and monitoring,Hypertension: monitor blood pressure and initiate antihypertensive therapy as needed,Second primary malignancies: including skin cancers and other carcinomas,Hepatotoxicity: elevations in liver enzymes; monitor hepatic function,Embryo-fetal toxicity: can cause fetal harm; advise women of reproductive potential to avoid pregnancy
Hemorrhage: Fatal bleeding events have occurred; monitor for bleeding and manage appropriately,Infections: Serious infections (including opportunistic infections) have occurred; consider prophylaxis,Cytopenias: Grade 3/4 neutropenia, thrombocytopenia, and anemia; monitor blood counts,Second primary malignancies: Including skin cancers; advise sun protection,Atrial fibrillation and flutter: Monitor for cardiac arrhythmias,Hepatotoxicity: Elevations of liver enzymes; monitor hepatic function
None
None
Avoid grapefruit, grapefruit juice, Seville oranges, and pomelos. These fruits inhibit CYP3A4 and increase ibrutinib levels, raising toxicity risk (bleeding, arrhythmias). No other significant food interactions.
Avoid grapefruit, grapefruit juice, and Seville oranges due to CYP3A4 inhibition increasing acalabrutinib exposure. No other significant food interactions.
Embryo-fetal toxicity risk. Based on mechanism of action (Bruton's tyrosine kinase inhibitor) and animal studies, there is potential for teratogenicity. Avoid use during pregnancy unless benefit outweighs risk. For first trimester: high risk due to critical organogenesis; second and third trimesters: may cause fetal harm, including low birth weight and developmental abnormalities.
Acalabrutinib is a BTK inhibitor. Animal studies show embryo-fetal toxicity including malformations and reduced fetal weight at maternal exposures below clinical doses. In humans, no adequate data; however, based on mechanism and animal findings, there is potential risk of teratogenicity, especially during first trimester. Use during pregnancy should be avoided unless maternal benefit outweighs fetal risk.
No data on presence in human milk, effects on breastfed infant, or milk production. Due to potential for serious adverse reactions, advise women not to breastfeed during treatment and for at least 1 week after last dose. M/P ratio unknown.
No data on acalabrutinib in human milk. Based on molecular weight and pharmacokinetics, excretion into breast milk is likely. M/P ratio unknown. Because of potential serious adverse reactions in breastfed infants, advise not to breastfeed during treatment and for 2 weeks after last dose.
No specific dose adjustments established. Consider alternative therapy if pregnancy occurs. Systemic exposure may decrease due to increased plasma volume and hepatic metabolism, but no PK data in pregnancy. Do not adjust dose; discontinue if pregnancy occurs unless benefit justifies risk.
No established dosing adjustments for pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) may affect exposure; however, no specific dose recommendations are available. If used, therapeutic drug monitoring is not established; close clinical monitoring for efficacy and toxicity is advised.
Monitor for atrial fibrillation (ECG if palpitations), bleeding risk due to antiplatelet effect (hold 3-7 days before surgery), and tumor lysis syndrome (especially CLL with high lymphocytosis). CYP3A4 substrate: avoid strong inhibitors (ketoconazole, clarithromycin) and reduce dose with moderate inhibitors (fluconazole, diltiazem). Check for HBV reactivation before starting.
Monitor for bleeding, especially if on antiplatelet or anticoagulant therapy. Acalabrutinib is a selective BTK inhibitor with minimal off-target effects compared to ibrutinib, but still carries risks of atrial fibrillation, hypertension, and infections. Start with 100 mg twice daily until progression or unacceptable toxicity. Administer with a full glass of water; do not open capsules. Consider dose reduction for severe hepatic impairment (Child-Pugh C).
Take with a full glass of water at the same time each day. Swallow capsules whole, do not open, break, or chew.,Do not drink grapefruit juice, Seville oranges, or pomelos while taking this medication.,Report any new or worsening bruising, bleeding, black/tarry stools, or pink/dark urine immediately.,Seek medical attention for symptoms of atrial fibrillation like palpitations, chest discomfort, or shortness of breath.,Avoid activities that increase bleeding risk (e.g., contact sports) until you know how the drug affects you.,Inform all healthcare providers (including dentists) that you are taking ibrutinib before any procedures.
Take exactly as prescribed, twice daily about 12 hours apart.,Swallow capsules whole with water; do not crush or chew.,Avoid grapefruit, grapefruit juice, and Seville oranges during treatment.,Report any signs of bleeding (unusual bruising, black/tarry stools, blood in urine) or infection (fever, chills) immediately.,Use effective contraception during treatment and for at least 1 week after last dose.,Do not stop or change dose without consulting your doctor.,Wash hands frequently and avoid crowds to reduce infection risk.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IMBRUVICA vs ACALABRUTINIB, answered by our medical review team.
IMBRUVICA is a BTK Inhibitor that works by Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in the BTK active site, leading to irreversible inhibition of BTK activity. BTK is a key signaling molecule in the B-cell antigen receptor (BCR) and cytokine receptor pathways, which are involved in the survival, proliferation, and migration of malignant B cells.. ACALABRUTINIB is a BTK Inhibitor that works by Acalabrutinib is a selective, irreversible inhibitor of Bruton tyrosine kinase. It forms a covalent bond with a cysteine residue in the active site, blocking B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IMBRUVICA and ACALABRUTINIB depend on the specific clinical indication. These are both BTK Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IMBRUVICA is: 560 mg orally once daily for mantle cell lymphoma; 420 mg orally once daily for chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease.. The standard adult dose of ACALABRUTINIB is: 100 mg orally every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IMBRUVICA and ACALABRUTINIB in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IMBRUVICA is classified as Category C. Embryo-fetal toxicity risk. Based on mechanism of action (Bruton's tyrosine kinase inhibitor) and animal studies, there is potential for teratogenicity. Avoid use during pregnancy . ACALABRUTINIB is classified as Category C. Acalabrutinib is a BTK inhibitor. Animal studies show embryo-fetal toxicity including malformations and reduced fetal weight at maternal exposures below clinical doses. In humans, . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.